Cantor Fitzgerald Reiterates “Overweight” Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Cantor Fitzgerald reiterated their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $13.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms also recently commented on MRNS. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, August 14th. StockNews.com raised Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, September 9th. HC Wainwright reaffirmed a buy rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Truist Financial reaffirmed a buy rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Marinus Pharmaceuticals currently has an average rating of Hold and an average price target of $10.25.

Marinus Pharmaceuticals Stock Performance

MRNS opened at $1.60 on Monday. The business has a 50 day moving average price of $1.37 and a two-hundred day moving average price of $2.92. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15. The company has a market capitalization of $87.89 million, a price-to-earnings ratio of -0.61 and a beta of 1.13. Marinus Pharmaceuticals has a 1-year low of $1.05 and a 1-year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The firm had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. During the same quarter last year, the company earned ($0.61) EPS. Research analysts predict that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Point72 DIFC Ltd acquired a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $28,000. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals in the 2nd quarter valued at approximately $34,000. AQR Capital Management LLC lifted its position in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at $64,000. Finally, Values First Advisors Inc. grew its holdings in shares of Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 52,257 shares in the last quarter. 98.80% of the stock is owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.